Novel bovine tuberculosis biomarker and use thereof
A biomarker composition using genes like RUBCNL, CXCL1, CXCL2, SMIM7, CTSW, TAC3, IL2, and NRADD facilitates early and accurate diagnosis of bovine tuberculosis, addressing the challenge of unclear symptoms and improving detection sensitivity and specificity.
Patent Information
- Application Number
- PCT/KR2024/006624
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-05-14
- Filing Date
- 2024-05-16
- Publication Date
- 2024-11-21
AI Technical Summary
Bovine tuberculosis is challenging to diagnose early due to unclear symptoms, leading to delayed detection and potential spread among animals, and existing diagnostic methods lack high accuracy and sensitivity, especially in asymptomatic carriers.
A biomarker composition comprising specific genes such as RUBCNL, CXCL1, CXCL2, SMIM7, CTSW, TAC3, IL2, and NRADD, along with associated agents like primers, probes, and antibodies, is developed to measure gene expression levels for accurate diagnosis and prediction of bovine tuberculosis.
The biomarker composition achieves high sensitivity and specificity, enabling early and accurate detection of bovine tuberculosis, even in asymptomatic animals, and aids in selecting effective treatments by analyzing gene expression changes.
Smart Images

Figure KR2024006624_21112024_PF_FP_ABST
Abstract
Description
Novel tuberculosis biomarkers and their uses
[0001] The present invention relates to a novel biomarker for diagnosing tuberculosis, a diagnostic or predictive composition comprising the same, a kit comprising the same, and uses thereof.
[0002] Bovine tuberculosis (TB) is a zoonotic disease, rapidly transmitted directly or indirectly from cattle with pulmonary lesions or severe cases of udder TB, such as udder TB. Cattle with severe pulmonary TB or systemic infection may exhibit symptoms such as coughing, loss of coat luster, loss of appetite, loss of energy, decreased milk flow, and emaciation. However, because no abnormalities are apparent, the diagnosis is often made after autopsy.
[0003] Diagnosis of bovine tuberculosis includes a pure protein derivative skin test, an intradermal test using PPD (purified protein derivative, tuberculin skin test), and a diagnostic method using immune cell culture, such as the lymphocyte transformation test (LTT). Methods for confirming bacterial infection include tuberculosis isolation and identification, PCR, and HPLC, and an ELISA gamma interferon diagnostic kit (bovine tuberculosis antibody ELISA) that uses a method for detecting antibodies to tuberculosis bacilli is commonly used.
[0004] However, tuberculosis can be transmitted by individuals without specific clinical symptoms. Because early diagnosis is difficult, culling infected individuals upon detection is a reliable means of quarantine. In particular, wild animals also serve as reservoirs for tuberculosis, making it crucial to control the spread of tuberculosis from wild animals to livestock.
[0005] Under these circumstances, there is a continuous need for the development of technologies to detect or diagnose tuberculosis, and in particular, there is a continuous need for the discovery of biomarkers and the development of diagnostic technologies that enable early and accurate diagnosis of tuberculosis to enable early response to the disease.
[0006] The purpose of the present invention is to provide a biomarker composition for diagnosing or predicting tuberculosis.
[0007] Another object of the present invention is to provide a composition for diagnosing or predicting tuberculosis.
[0008] Another object of the present invention is to provide a kit for diagnosing or predicting tuberculosis comprising the above diagnostic or predictive composition.
[0009] Another object of the present invention is to provide a method for providing information for diagnosing or predicting tuberculosis.
[0010] Another object of the present invention is to provide a method for diagnosing tuberculosis.
[0011] Another object of the present invention is to provide a method for screening a treatment agent for tuberculosis.
[0012] One aspect of the present invention for achieving the above-mentioned purpose relates to a biomarker composition for diagnosing or predicting tuberculosis, comprising one or more genes selected from the group consisting of RUBCNL (Rubicon like autophagy enhancer), CXCL1 (Chemokine (CXC motif) ligand 1), CXCL2 (Chemokine (CXC motif) ligand 2), SMIM7 (Small Integral Membrane Protein 7), CTSW (Cathepsin W), TAC3 (Tachykinin Precursor 3), IL2 (Interleukin 2), and NRADD (Neurotrophin receptor associated death domain protein).
[0013] Also, specifically, the RUBCNL may be composed of a base sequence of sequence number 1, the CXCL1 may be composed of a base sequence of sequence number 2, the CXCL2 may be composed of a base sequence of sequence number 3, the SMIM7 may be composed of a base sequence of sequence number 4, the CTSW may be composed of a base sequence of sequence number 5, the TAC3 may be composed of a base sequence of sequence number 6, the IL2 may be composed of a base sequence of sequence number 7, and the NRADD may be composed of a base sequence of sequence number 8.
[0014] In the present invention, "Bovine Tuberculosis" is also called pearl disease and is a chronic wasting zoonotic disease. It is caused by Mycobacterium bovis (M. bovis), and the main infection route is small droplets contained in the cough of an infected animal or feed contaminated with saliva, and it can also be transmitted through ingestion of unpasteurized raw milk or through feces, placenta, etc. Since the disease progresses slowly and the symptoms are not obvious, it is difficult to find infected animals, and therefore, infected animals that do not show symptoms often spread the disease to other animals living together.
[0015] In the present invention, a "biomarker" is an indicator that can measure changes in a living body using DNA, RNA, proteins, metabolites, etc., and can be used to measure the occurrence of a disease in a living body, the presence of an infection, the degree of drug response, etc.
[0016] In the present invention, a “gene” is a factor that expresses a genetic trait of an organism, and may include a nucleic acid material composed of bases or modified bases, such as DNA or RNA.
[0017] In this outbreak example, it was confirmed that newly discovered biomarkers, RUBCNL, CXCL1, CXCL2, SMIM7, CTSW, TAC3, IL2 and / or NRADD, can exhibit very high accuracy by showing high AUC values of 0.8 or 0.9 or higher in ROC analysis.
[0018] Another aspect of the present invention relates to a composition for diagnosing or predicting tuberculosis, comprising a preparation for measuring the expression level of one or more gene expression products selected from the group consisting of RUBCNL, CXCL1, CXCL2, SMIM7, CTSW, TAC3, IL2, and NRADD or for determining whether there is a mutation.
[0019] Specifically, the gene expression product may be, but is not limited to, an mRNA, a protein or a fragment thereof encoded by one or more genes selected from the group consisting of RUBCNL, CXCL1, CXCL2, SMIM7, CTSW, TAC3, IL2 and NRADD.
[0020] In the present invention, the “agent” may be one or more selected from the group consisting of sense or antisense primers, probes, aptamers, antibodies, peptides, and nucleotides that specifically bind to a gene expression product, but is not limited thereto.
[0021] The above 'primer' refers to a short nucleic acid sequence having a short free 3' terminal hydroxyl group, which can form base pairs with a complementary template and serves as a starting point for copying the template strand. The primer can initiate DNA synthesis in the presence of a reagent for polymerization (i.e., DNA polymerase or reverse transcriptase) and different nucleoside triphosphates in an appropriate buffer and temperature. PCR conditions and the lengths of the sense and antisense primers can be modified based on those known in the art.
[0022] The above 'probe' refers to a nucleic acid fragment such as RNA or DNA, which is a few bases at the shortest and several tens of bases at the longest. The probe can be produced in the form of an oligonucleotide probe, a single-stranded DNA probe, a double-stranded DNA probe, an RNA probe, etc. The DNA can include cDNA, genomic DNA, and oligonucleotides, the RNA can include genomic RNA, mRNA, and oligonucleotides, and the protein can include antibodies, antigens, enzymes, peptides, etc. The selection of an appropriate probe, hybridization conditions, and whether or not to label can be modified based on those known in the art.
[0023] The above-mentioned "aptamer" is a single-stranded nucleic acid (DNA, RNA, or modified nucleic acid) substance with a tertiary structure and the ability to bind to a target molecule with high affinity and specificity. As a nucleic acid substance, it can undergo various modifications and can be applied for diagnostic or predictive purposes by binding to the gene expression product of the present invention and allowing the expression level to be measured.
[0024] The above 'antibody' refers to a specific protein molecule directed against an antigenic site. The antibody may refer to a protein molecule that specifically binds to a tuberculosis biomarker according to an example, and may include a polyclonal antibody, a monoclonal antibody, or an immunoglobulin antibody, and may also include a special antibody such as a humanized antibody. In addition, the antibody may include a complete form having two full-length light chains and two full-length heavy chains, as well as a functional fragment of an antibody molecule. The functional fragment of the antibody molecule refers to a fragment that has at least an antigen-binding function, and may include Fab, F(ab'), F(ab')2, Fv, etc.
[0025] The above 'peptide' refers to all forms including an amino acid sequence that can specifically bind to a gene expression product, and the length, form, labeling, etc. of the peptide can be appropriately modified and applied as needed.
[0026] The above 'nucleotide' refers to all forms containing nucleic acids such as RNA, DNA, and PNA that can complementarily bind to a gene expression product, and the length, shape, labeling, etc. of the nucleotide can be appropriately modified and applied as needed.
[0027] In the present invention, “diagnosis” includes determining the susceptibility of an object, i.e., a test subject, to a specific disease or condition, determining whether an object currently has a specific disease or condition, determining the prognosis of an object suffering from a specific disease or condition, or therametrics (e.g., monitoring the condition of an object to provide information on the efficacy of a treatment).
[0028] In the present invention, “prediction” means to guess in advance about the medical outcome, and refers to guessing in advance the progression, improvement, relapse, relapse after drug treatment, or survival of a disease.
[0029] Another aspect of the present invention relates to a composition for diagnosing or predicting bovine tuberculosis, comprising the biomarker composition for diagnosing or predicting bovine tuberculosis. The composition may comprise one or more genes selected from the group consisting of RUBCNL, CXCL1, CXCL2, SMIM7, CTSW, TAC3, IL2, and NRADD, together with a carrier, excipient, additive, or agent capable of measuring the expression of the biomarker gene, as needed, but is not limited thereto.
[0030] Another aspect of the present invention relates to a kit for diagnosing or predicting tuberculosis, comprising the composition for diagnosing or predicting tuberculosis.
[0031] The kit of the present invention can be used to diagnose the presence or absence of tuberculosis by measuring the expression level of a biomarker gene in the blood, serum, urine, etc. of an individual suspected of having tuberculosis, and can be configured to include, without limitation, components, solutions, devices, etc. necessary for measurement or analysis, such as primers, probes, and antisense nucleotides capable of measuring the expression level of the gene. For example, it can include, but is not limited to, an RT-PCR (Reverse transcription polymerase chain reaction) kit, a DNA chip kit, a microarray chip kit, a protein chip kit, etc.
[0032] The above diagnostic kit may be in the form of a solution, lyophilized powder, frozen solution, or strip, each of which may be formulated by a method conventional in the art. The kit may also include instructions for use.
[0033] Another aspect of the present invention relates to a method for providing information for diagnosing or predicting tuberculosis, comprising the steps of: a) measuring the expression level of one or more genes selected from the group consisting of RUBCNL, CXCL1, CXCL2, SMIM7, CTSW, TAC3, IL2, and NRADD in a sample isolated from an individual; and b) comparing the gene expression level with the corresponding gene expression level of a normal control sample.
[0034] Specifically, if the expression level of the above RUBCNL, CXCL1 or CXCL2 is decreased compared to the normal control group, a step of determining that it is tuberculosis may be additionally included.
[0035] Additionally, specifically, if the expression level of SMIM7, CTSW, TAC3, IL2 or NRADD increases compared to the normal control group, a step of determining that it is tuberculosis may be additionally included.
[0036] In the present invention, the sample may be blood, tissue, cells, whole blood, plasma, serum, saliva, sputum, lymph, spinal fluid, intercellular fluid, or urine, and as long as it corresponds to a sample that can be applied to the diagnosis of tuberculosis, it can be applied as a sample without being limited to the above examples.
[0037] Another aspect of the present invention relates to a method for diagnosing tuberculosis, comprising the steps of: a) measuring the expression level of one or more genes selected from the group consisting of RUBCNL, CXCL1, CXCL2, SMIM7, CTSW, TAC3, IL2, and NRADD in a sample isolated from an individual; and b) comparing the gene expression level with the corresponding gene expression level of a normal control sample.
[0038] Specifically, if the expression level of the above RUBCNL, CXCL1 or CXCL2 is decreased compared to the normal control group, a step of determining that it is tuberculosis may be additionally included.
[0039] Additionally, specifically, if the expression level of SMIM7, CTSW, TAC3, IL2 or NRADD increases compared to the normal control group, a step of determining that it is tuberculosis may be additionally included.
[0040] The sample in the diagnostic method of the present invention may be blood, tissue, cells, whole blood, plasma, serum, saliva, sputum, lymph, spinal fluid, intercellular fluid, or urine, and as long as it corresponds to a sample that can be applied to the diagnosis of tuberculosis, it may be applied as a sample without being limited to the above examples.
[0041] In addition, another aspect of the present invention relates to a method for screening a treatment agent for tuberculosis, comprising the steps of: a) treating a sample with a candidate substance for the treatment agent for tuberculosis; and b) measuring the expression level of one or more genes selected from the group consisting of RUBCNL, CXCL1, CXCL2, SMIM7, CTSW, TAC3, IL2, and NRADD in the sample treated with the candidate substance.
[0042] Specifically, if the expression level of RUBCNL, CXCL1 or CXCL2 measured in step b) above is increased compared to a sample not treated with the candidate substance, a step of determining the treated candidate substance as a treatment for tuberculosis may be additionally included.
[0043] In addition, specifically, if the expression level of SMIM7, CTSW, TAC3, IL2 or NRADD measured in step b) is reduced compared to a sample not treated with the candidate substance, a step of determining the treated candidate substance as a treatment for tuberculosis may be additionally included.
[0044] In one embodiment of the present invention, it was confirmed that RUBCNL, CXCL1, CXCL2, SMIM7, CTSW, TAC3, IL2 and / or NRADD were increased or decreased in bovine tuberculosis-infected cattle compared to normal cattle, and it was confirmed through ROC analysis that when the genes are used as biomarkers, bovine tuberculosis-infected cattle can be distinguished with high sensitivity and accuracy. Accordingly, when the expression of RUBCNL, CXCL1 or CXCL2, which was decreased, is increased or the expression of SMIM7, CTSW, TAC3, IL2 or NRADD, which was increased, is decreased according to candidate substance treatment, the subject can be selected as a bovine tuberculosis treatment agent.
[0045] The novel biomarker of the present invention and / or compositions comprising the same can enable rapid and accurate diagnosis and / or prediction of tuberculosis, a condition where symptoms are unclear and thus it is difficult to determine whether infection or development has occurred. In particular, the biomarker of the present invention has high sensitivity and specificity, and thus can be used not only for the diagnosis and / or prediction of tuberculosis but also for the selection of treatment agents for tuberculosis.
[0046] The effects of the present invention are not limited to the effects described above, and should be understood to include all effects that can be inferred from the detailed description of the present invention or the composition of the invention described in the claims.
[0047] Figure 1 shows the gene biomarkers with increased expression when comparing normal cattle and cattle infected with tuberculosis.
[0048] Figure 2 shows the comparison of expression levels of RUBCNL and CXCL1 with expression changes and the results of ROC analysis by comparing normal cows and cows infected with tuberculosis.
[0049] Figure 3 shows the comparison of expression levels of CXCL2, SMIM7, and TAC3 with expression changes in normal cows and cows infected with tuberculosis, and the results of ROC analysis.
[0050] Figure 4 shows the results of ROC analysis for the IL2, CTSW, and NRADD biomarkers.
[0051] Hereinafter, the present invention will be described in detail by way of examples. However, the following examples are only illustrative of the present invention, and the present invention is not limited to the following examples.
[0052] Example 1. RNA extraction and purification from bovine blood samples
[0053] Blood samples were collected from bovine tuberculosis-negative and -positive cows, whose infection with bovine tuberculosis was confirmed using the PPD intradermal test and ELISA gamma interferon diagnostic kit. Total RNA was extracted from the obtained blood samples using XENOPURE. TM Total RNA Purification Kit (XENOHELIX, Cat, No. 93667873-TR) was used.
[0054] Specifically, 750 μl of XENOPURE was added to 250 μl of blood sample. TM-TR Lysis Buffer was added and vortexed for 1 minute, centrifuged at 12,300 xg for 1 minute, and the supernatant was transferred to a new 1.5 ml microcentrifuge tube. 200 μl of chloroform was added and vortexed for 30 seconds to mix well. Incubate at room temperature for 3 minutes, centrifuge at 4°C and 12,300 xg for 10 minutes, and then 300 μl of the upper aqueous phase was transferred to a DNA removal column and centrifuged at 12,300 xg for 1 minute. The column containing the genomic DNA was discarded, and the flow-through collected in the collection tube was transferred to a new 1.5 ml microcentrifuge tube, and an equal amount of binding solution-Total RNA (BS-TR) was added to the tube containing the flow-through and mixed gently.
[0055] XENOPURE with a 2 ml collection tube containing the mixture TM The RNA was added to the column and centrifuged at 2,000 xg for 1 minute at room temperature, and the flow-through filtered into a collection tube was discarded.
[0056] Afterwards, add 700 μl of Washing buffer 1 (WB 1) to XENOPURE TM The RNA was added to the column and centrifuged at 2,000 xg for 1 minute at room temperature. The flow-through filtered into the collection tube was discarded. 700 μl of Washing buffer 2 (WB 2) was added again to XENOPURE TMThe RNA was added to the column and centrifuged at 2,000 xg for 1 minute at room temperature. The flow-through filtered into the collection tube was discarded. 700 μl of Washing buffer 3 (WB 3) was added again to XENOPURE TM The RNA was added to the column and centrifuged at 2,000 xg for 1 minute at room temperature, and the flow-through filtered into a collection tube was discarded.
[0057] After XENOPURE TM The RNA column was placed in a new 2 ml collection tube, centrifuged at 12,300 xg for 3 minutes with the column lid open to dry the membrane, and the collection tube and flow-through were discarded. XENOPURE TM Place the RNA column in a new 1.5 ml microcentrifuge tube and XENOPURE TM 40 μl of Elution Buffer (EB) was added to the RNA column membrane. After closing the column lid, centrifugation was performed at 12,300 xg for 2 minutes to obtain total RNA.
[0058] Example 2. cDNA synthesis
[0059] The RNA obtained in Example 1 was quantified using a Nanodrop device, and 100 ng was placed in a tube using XENO cDNA Synthesis Kit-TB (XENOHELIX, Cat, No. 9366CTB). Then, 5 μl of XENO 4X RT Reaction Mix-TB and 1 μl of XENO RTase mix were added, and finally, nuclease-free water was added to make the final solution volume 20 μl, mixed well, and reacted at 25°C for 5 minutes, 50°C for 20 minutes, and 95°C for 1 minute, and cooled to 4°C to generate cDNA strands. The synthesized cDNA product was stored frozen at -20°C.
[0060] Example 3. qPCR
[0061] 2 μl of cDNA synthesized through the above Example 2, 1 μl of target gene-specific forward primer (10 pmol / μl), 1 μl of reverse primer (10 pmol / μl), 0.5 μl of target gene-specific probe (10 pmol / μl), 12.5 μl of qPCR mixture (XENOHELIX, Cat, No.9366XPM), and 8 μl of DW were mixed to a final volume of 25 μl. The mixture was added to a 96-well qPCR plate and the qPCR reaction was performed. The BioRad CFX Connect Real-Time PCR Detection System was used, and PCR was performed under the conditions of 1 cycle of 95 °C for 5 minutes, 40 cycles of 95 °C for 15 seconds, and 63 °C for 1 minute. The relative expression level of the target gene was calculated based on the Cq value obtained through CFX Maestro qPCR Analysis Software.
[0062] The primer and probe sequences used in the present invention are as follows. β-actin was used as a reference gene for comparing gene expression.
[0063] [Table 1]
[0064]
[0065] Example 4. Identification of biomarkers for the diagnosis and prediction of tuberculosis.
[0066] 4-1. Discovery of Tuberculosis Biomarkers
[0067] Through the processes of Examples 1 to 3 above, a new biomarker capable of detecting bovine tuberculosis was discovered by detecting a decrease or increase in gene expression in blood samples from bovine tuberculosis-infected cattle compared to normal cattle.
[0068] For example, as shown in Figure 1, CTSW, IL2, and NRADD were selected as genes whose expression was significantly increased in bovine tuberculosis-infected cattle compared to normal cattle. In addition, as shown in Figures 2 and 3, RUBCNL, CXCL1, and CXCL2 were selected as genes whose expression was decreased in bovine tuberculosis-infected cattle compared to normal cattle, and SMIM7 and TAC3 were selected as genes whose expression was increased in bovine tuberculosis-infected cattle compared to normal cattle. The selected bovine tuberculosis biomarkers are summarized in Table 2 below.
[0069] [Table 2]
[0070]
[0071] 4-3. Validation of Tuberculosis Biomarkers
[0072] In order to verify the sensitivity and specificity of the biomarker discovered in the above 4-1, the area under the ROC curve (AUC) value of the receiver operating characteristic (ROC) was confirmed. The ROC analysis is a graph that expresses the correlation between sensitivity and specificity in a specific diagnostic method, and can indicate the accuracy of a specific diagnostic model. "Sensitivity" in the present invention means the rate at which individuals with an actual disease are judged as positive when a specific diagnostic model is used, and "specificity" in the present invention means the rate at which individuals without an actual disease are judged as negative when a specific diagnostic model is used.
[0073] In this ROC analysis, if both the specificity and sensitivity are high, the accuracy of the test increases. For example, when the total area is 1, the accuracy can be judged to be higher when the AUC is 0.5 or more, 0.6 or more, 0.7 or more, 0.8 or more, or 0.9 or more. In the ROC graph, the closer the curve is to the upper left corner, the higher the accuracy can be judged. In addition, in the ROC curve, the larger the area under the curve (AUC), the higher the accuracy of the corresponding diagnostic model can be judged.
[0074] As a result, as shown in Fig. 2, RUBCNL and CXCL1 showed high AUC values of 0.9 or more, although their expression was reduced compared to normal cows, confirming their high accuracy as biomarkers.
[0075] In addition, as shown in Fig. 3, CXCL2 showed a significantly high AUC value of approximately 1.0 despite its decreased expression compared to normal cows, confirming its high accuracy as a biomarker. SMIM7 and TAC3 showed a significantly high AUC value of approximately 1.0 despite its increased expression compared to normal cows, confirming its high accuracy as a biomarker.
[0076] In addition, as shown in Fig. 4, IL2 showed a high AUC value of 0.8 or higher, and CTSW and NRADD showed high AUC values of 0.9 or higher, confirming their high accuracy as biomarkers.
[0077] The above results show that the biomarker discovered in the present invention has extremely high specificity and sensitivity for tuberculosis, and can detect and diagnose tuberculosis with very high accuracy.
[0078] The above biomarkers can be applied individually or in combination to meaningfully diagnose tuberculosis, and can also predict the occurrence of tuberculosis with only gene expression information for tuberculosis with no obvious symptoms.
[0079] All statistical analyses in the present invention applied analysis of variance (ANOVA) to evaluate the differences between each group, and the diagnostic value for each biomarker was calculated by analyzing the receiver operating characteristic curve (ROC) and the area under the ROC curve (AUC). The optimal statistical cutoff value was calculated based on the ROC curve using the Wilson / Brown method, one of the methods for estimating confidence intervals, and then the sensitivity, specificity, accuracy, positive predictive value, and negative predictive value for the selected cutoff point were evaluated using the generalized estimating equation method. All statistical analyses in the present invention were performed using GraphPad Prism 9.5.1 (GraphPad Software, Boston, MA, USA), and a p-value less than 0.0001 was considered statistically significant.
[0080] The foregoing description of the present invention is for illustrative purposes only, and those skilled in the art will readily appreciate that the present invention can be readily modified into other specific forms without altering the technical spirit or essential characteristics of the present invention. Therefore, the embodiments described above should be understood as illustrative in all respects and not restrictive. For example, each component described as a single entity may be implemented in a distributed manner, and similarly, components described as distributed may be implemented in a combined manner.
[0081] The scope of the present invention is indicated by the claims set forth below, and all changes or modifications derived from the meaning and scope of the claims and their equivalent concepts should be interpreted as being included in the scope of the present invention.
Claims
1. A biomarker composition for diagnosing or predicting tuberculosis, comprising one or more genes selected from the group consisting of RUBCNL (Rubicon like autophagy enhancer), CXCL1 (Chemokine (CXC motif) ligand 1), CXCL2 (Chemokine (CXC motif) ligand 2), SMIM7 (Small Integral Membrane Protein 7), CTSW (Cathepsin W), TAC3 (Tachykinin Precursor 3), IL2 (Interleukin 2), and NRADD (Neurotrophin receptor associated death domain protein).
2. In paragraph 1, The above RUBCNL consists of the base sequence of sequence number 1, The above CXCL1 is composed of the base sequence of sequence number 2, The above CXCL2 is composed of the base sequence of sequence number 3, The above SMIM7 is composed of the base sequence of sequence number 4, The above CTSW consists of the base sequence of sequence number 5, The above TAC3 consists of the base sequence of sequence number 6, The above IL2 is composed of the base sequence of sequence number 7, The above NRADD is a biomarker composition for diagnosing or predicting tuberculosis, which is composed of a base sequence of sequence number 8.
3. A composition for diagnosing or predicting tuberculosis, comprising a preparation for measuring the expression level of one or more gene expression products selected from the group consisting of RUBCNL, CXCL1, CXCL2, SMIM7, CTSW, TAC3, IL2, and NRADD or for determining whether there is a mutation.
4. In paragraph 3, A composition for diagnosing or predicting tuberculosis, wherein the gene expression product is an mRNA, protein or fragment thereof encoded by one or more genes selected from the group consisting of RUBCNL, CXCL1, CXCL2, SMIM7, CTSW, TAC3, IL2 and NRADD.
5. In paragraph 3, A composition for diagnosing or predicting tuberculosis, wherein the above formulation comprises at least one selected from the group consisting of a sense or antisense primer, probe, aptamer, antibody, peptide, and nucleotide capable of specifically binding to a gene expression product.
6. A composition for diagnosing or predicting tuberculosis, comprising the biomarker composition of paragraph 1.
7. A kit for diagnosing or predicting tuberculosis, comprising a composition according to any one of claims 3 to 6. 8.a) a step of measuring the expression level of one or more genes selected from the group consisting of RUBCNL, CXCL1, CXCL2, SMIM7, CTSW, TAC3, IL2 and NRADD in a sample isolated from the subject; and b) A method for providing information for diagnosing or predicting tuberculosis, comprising a step of comparing the gene expression level with the corresponding gene expression level of a normal control sample.
9. In paragraph 8, A method for providing information for diagnosing or predicting tuberculosis, further comprising a step of determining tuberculosis when the expression level of RUBCNL, CXCL1 or CXCL2 is decreased compared to a normal control group.
10. In paragraph 8, A method for providing information for diagnosing or predicting tuberculosis, further comprising a step of determining tuberculosis when the expression level of SMIM7, CTSW, TAC3, IL2 or NRADD is increased compared to a normal control group.
11. In paragraph 8, A method for providing information for diagnosing or predicting tuberculosis, wherein the sample is blood, tissue, cells, whole blood, plasma, serum, saliva, sputum, lymph, spinal fluid, interstitial fluid or urine. 12.a) a step of treating the sample with a candidate substance for the treatment of tuberculosis; and b) A method for screening a treatment agent for tuberculosis, comprising the step of measuring the expression level of one or more genes selected from the group consisting of RUBCNL, CXCL1, CXCL2, SMIM7, CTSW, TAC3, IL2, and NRADD in a sample treated with the candidate substance.
13. In paragraph 12, A method for screening for a treatment for tuberculosis, further comprising a step of determining that the treated candidate substance is a treatment for tuberculosis if the expression level of RUBCNL, CXCL1 or CXCL2 measured in step b) above is increased compared to that in a sample not treated with the candidate substance.
14. In paragraph 12, A method for screening a treatment for tuberculosis, further comprising a step of determining that the treated candidate substance is a treatment for tuberculosis if the expression level of SMIM7, CTSW, TAC3, IL2 or NRADD measured in step b) above is reduced compared to that in a sample not treated with the candidate substance. 15.a) a step of measuring the expression level of one or more genes selected from the group consisting of RUBCNL, CXCL1, CXCL2, SMIM7, CTSW, TAC3, IL2 and NRADD in a sample isolated from an individual; and b) A method for diagnosing tuberculosis, comprising a step of comparing the gene expression level with the corresponding gene expression level of a normal control sample.
16. In paragraph 15, A method for diagnosing tuberculosis, further comprising a step of determining that it is tuberculosis when the expression level of RUBCNL, CXCL1 or CXCL2 is decreased compared to a normal control group.
17. In paragraph 15, A method for diagnosing tuberculosis, further comprising a step of determining tuberculosis when the expression level of SMIM7, CTSW, TAC3, IL2 or NRADD is increased compared to a normal control group.
18. In paragraph 15, A method for diagnosing tuberculosis, wherein the sample is blood, tissue, cells, whole blood, plasma, serum, saliva, sputum, lymph, spinal fluid, interstitial fluid or urine.
Citation Information
Patent Citations
Flow cytometry detection kit for diagnosing bovine tuberculosis
CN107831316A
Intradermal diagnostic composition for cattle tuberculosis intradermal test and diagnostic method using the same
KR1020110052295A
A Diagnostic Kit for simultaneously detection of Clinical Strains of Mycobacterium tuberculosis, Mycobacterium bovis and / or Mycoabcterium bovis BCG and method using the same
KR1020130141919A
Diagnostic markers for bovine tuberculosis and uses thereof
US20200264193A1
Cited By
Application of NmrAL2Bovine gene as target spot in prevention and treatment of bovine tuberculosis
CN119524133A
